Diane Warren

4.8k total citations
40 papers, 1.0k citations indexed

About

Diane Warren is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Diane Warren has authored 40 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 20 papers in Hematology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Diane Warren's work include Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Diane Warren is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (15 papers) and Multiple Myeloma Research and Treatments (14 papers). Diane Warren collaborates with scholars based in United States and New Zealand. Diane Warren's co-authors include Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson, Stacey Chuma, Edie Weller, Steven P. Treon, Brianna Harris, Renee Leduc, Janet Kunsman and Meghan Rourke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Diane Warren

39 papers receiving 987 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diane Warren United States	12	528	525	432	348	214	40	1.0k
David Hakimian United States	17	657 1.2×	295 0.6×	446 1.0×	209 0.6×	306 1.4×	48	1.1k
Ozren Jakšić Croatia	15	407 0.8×	227 0.4×	234 0.5×	184 0.5×	273 1.3×	55	857
Thomas E. Lew Australia	16	573 1.1×	211 0.4×	428 1.0×	219 0.6×	198 0.9×	33	880
Miguel‐Teodoro Hernández Spain	14	210 0.4×	796 1.5×	165 0.4×	597 1.7×	83 0.4×	44	1.2k
Luciano Levato Italy	13	440 0.8×	268 0.5×	257 0.6×	82 0.2×	189 0.9×	39	659
Gilles Lugassy Israel	16	254 0.5×	217 0.4×	224 0.5×	118 0.3×	191 0.9×	55	779
Amalia Vassou Greece	11	294 0.6×	262 0.5×	194 0.4×	148 0.4×	78 0.4×	23	507
Alain Sadoun France	12	209 0.4×	432 0.8×	158 0.4×	131 0.4×	142 0.7×	28	820
Joo-Seop Chung South Korea	14	155 0.3×	213 0.4×	310 0.7×	67 0.2×	200 0.9×	46	690
Abdulkadyrov Km Russia	11	282 0.5×	776 1.5×	88 0.2×	391 1.1×	83 0.4×	87	996

Countries citing papers authored by Diane Warren

Since Specialization

Citations

This map shows the geographic impact of Diane Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane Warren more than expected).

Fields of papers citing papers by Diane Warren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane Warren. The network helps show where Diane Warren may publish in the future.

Co-authorship network of co-authors of Diane Warren

This figure shows the co-authorship network connecting the top 25 collaborators of Diane Warren. A scholar is included among the top collaborators of Diane Warren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane Warren. Diane Warren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laubach, Jacob P., Sascha A. Tuchman, Jacalyn Rosenblatt, et al.. (2021). Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer Journal. 11(2). 20–20. 10 indexed citations

Varga, Cindy, Wanling Xie, Jacob P. Laubach, et al.. (2015). Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations. British Journal of Haematology. 169(6). 843–850. 60 indexed citations

Ghobrial, Irene M., Jacob P. Laubach, Kenneth H. Shain, et al.. (2014). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 5777–5777. 3 indexed citations

Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2012). The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal Of Haematology. 88(5). 446–449. 8 indexed citations

Warren, Diane. (2011). Implementation of a protocol for the prevention and management of extravasation injuries in the neonatal intensive care patient. International Journal of Evidence-Based Healthcare. 9(2). 165–171. 7 indexed citations

Sousa, Ângela Maria, Federico Campigotto, Donna Neuberg, et al.. (2011). Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients. Blood. 118(21). 5073–5073. 2 indexed citations

Treon, Steven P., Christina Tripsas, Leukothea Ioakimidis, et al.. (2011). Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. Blood. 118(21). 2951–2951. 10 indexed citations

Ghobrial, Irene M., Wanling Xie, Swaminathan P. Iyer, et al.. (2010). Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology. 85(9). 670–674. 101 indexed citations

Ghobrial, Irene M., Edie Weller, Ravi Vij, et al.. (2010). Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. Blood. 116(21). 990–990. 5 indexed citations

10.

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2010). Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1422–1428. 116 indexed citations

11.

Ghobrial, Irene M., Aldo M. Roccaro, Fangxin Hong, et al.. (2010). Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia. Clinical Cancer Research. 16(3). 1033–1041. 96 indexed citations

12.

Richardson, Paul G., Jacob P. Laubach, Constantine Mitsiades, et al.. (2010). Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.. PubMed. 24(3 Suppl 2). 22–9. 10 indexed citations

13.

Richardson, Paul G., Edie Weller, Sundar Jagannath, et al.. (2009). Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 27(34). 5713–5719. 127 indexed citations

14.

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood. 114(22). 2727–2727. 5 indexed citations

15.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. Blood. 112(11). 1010–1010. 2 indexed citations

16.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2007). Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4493–4493. 1 indexed citations

17.

Ghobrial, Irene M., Renee Leduc, Marybeth Nelson, et al.. (2007). Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4496–4496. 3 indexed citations

18.

Ghobrial, Irene M., Swaminathan P. Iyer, Ashraf Badros, et al.. (2007). Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4494–4494. 5 indexed citations

19.

Morris, Richard, et al.. (1988). The prevalence of hypoxemia detected by pulse oximetry during recovery from anesthesia. Journal of Clinical Monitoring and Computing. 4(1). 16–20. 32 indexed citations

20.

Raemer, Daniel B., Diane Warren, Richard Morris, Beverly K. Philip, & James H. Philip. (1987). Hypoxemia during Ambulatory Gynecologic Surgery as Evaluated by the Pulse Oximeter. The Journal of Clinical Monitoring. 3(4). 244–248. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact